Advertisement

Topics

Triumvira Immunologics Company Profile

11:45 EDT 19th April 2018 | BioPortfolio

Triumvira is developing an engineered T-cell technology called the T-Cell Antigen Coupler (TAC), developed in the laboratory of Dr. Jonathan Bramson at McMaster University in Hamilton, Ontario, and is designed to activate T-cells through the T-cell receptor complex. In multiple liquid and solid tumor animal models, TAC-T cells outperform CAR-T cells, with markedly improved pharmacodynamic effects and reduced toxicity. The company aims to enter the clinic a year from now, and is focusing its pipeline expansion on solid tumor targets. Not only does the TAC-T platform offer best-in-class potential, but the novel structure provides freedom to operate in a crowded space.


News Articles [5 Associated News Articles listed on BioPortfolio]

Triumvira Immunologics to Present at the 25th BioCentury Future Leaders Conference

Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced that it will pres...

Triumvira Immunologics Appoints Cynthia Collins to Board of Directors

Innovative immuno-therapy company welcomes a recognized leader in life sciences and therapeutics Triumvira Immunologics, a privately-held biopharmaceutical company deve...

Paul Lammers, M.D., M.Sc. Joins Triumvira as President and Chief Executive Officer

Experienced biotech executive takes helm of promising T-Cell Therapy company as it moves several programs toward clinical testing Triumvira Immunologics Canada Inc. and Triumv...

Triumvira Names a New CEO

Dr. Lammers brings more than 27 years of experience in product and clinical development spanning the pharmaceutical and biotechnology industries.

LaVoieHealthScience Expands Senior Leadership Team, Adds Two New Immuno-Oncology Clients to Roster

Douglas Russell joins LHS as Senior Vice President & General Manager LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advanc...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [4 Associated Companies listed on BioPortfolio]

Triumvira Immunologics

Triumvira is developing an engineered T-cell technology called the T-Cell Antigen Coupler (TAC), developed in the laboratory of Dr. Jonathan Bramson at McMaster University in Hami...

Signature Immunologics

Signature Immunologics produces anti-hapten IgGs for High Performance Immunocytochemistry (HPI), targeting key small molecules in cell physiology, including fast neurotransmitter amino acids and pivot...

Quantum Immunologics, Inc.

Signature Immunologics, Inc.

Nil

More Information about "Triumvira Immunologics" on BioPortfolio

We have published hundreds of Triumvira Immunologics news stories on BioPortfolio along with dozens of Triumvira Immunologics Clinical Trials and PubMed Articles about Triumvira Immunologics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Triumvira Immunologics Companies in our database. You can also find out about relevant Triumvira Immunologics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record